Bat-derived oligopeptide LE6 inhibits the contact-kinin pathway and harbors anti-thromboinflammation and stroke potential.
Anti-thromboinflammation
FXIIa
Ischemic stroke therapies
Oligopeptide
PK
Journal
Zoological research
ISSN: 2095-8137
Titre abrégé: Zool Res
Pays: China
ID NLM: 101697192
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
15
8
2024
Statut:
ppublish
Résumé
Thrombosis and inflammation are primary contributors to the onset and progression of ischemic stroke. The contact-kinin pathway, initiated by plasma kallikrein (PK) and activated factor XII (FXIIa), functions bidirectionally with the coagulation and inflammation cascades, providing a novel target for therapeutic drug development in ischemic stroke. In this study, we identified a bat-derived oligopeptide from 血栓形成和炎症是缺血性脑卒中的主要病因。由于血浆激肽释放酶（PK）和凝血因子XII（FXIIa）启动的接触-激肽通路与凝血和炎症级联反应具有双向作用，因此，为缺血性脑卒中治疗药物的开发提供了方向。该研究发现蝙蝠（
Autres résumés
Type: Publisher
(chi)
血栓形成和炎症是缺血性脑卒中的主要病因。由于血浆激肽释放酶（PK）和凝血因子XII（FXIIa）启动的接触-激肽通路与凝血和炎症级联反应具有双向作用，因此，为缺血性脑卒中治疗药物的开发提供了方向。该研究发现蝙蝠（
Identifiants
pubmed: 39147715
doi: 10.24272/j.issn.2095-8137.2023.372
pii:
doi:
Substances chimiques
Oligopeptides
0
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1001-1012Références
Aygören-Pürsün E, Bygum A, Grivcheva-Panovska V, et al. 2018. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine, 379(4): 352–362.
Aygören-Pürsün E, Magerl M, Graff J, et al. 2016. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology, 138(3): 934–936. e5.
Aygören-Pürsün E, Zanichelli A, Cohn DM, et al. 2023. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. The Lancet, 401(10375): 458–469.
Banerji A, Busse P, Shennak M, et al. 2017. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine, 376(8): 717–728.
Bird JE, Smith PL, Wang XK, et al. 2012. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the fletcher trait. Thrombosis and Haemostasis, 107(6): 1141–1150.
Bucciarelli V, Nasi M, Bianco F, et al. 2022. Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID syndrome: gender makes a difference. Trends in Cardiovascular Medicine, 32(1): 12–17.
Chamorro Á, Dirnagl U, Urra X, et al. 2016. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. The Lancet Neurology, 15(8): 869–881.
Chen ZL, Singh P, Wong J, et al. 2019. An antibody against HK blocks Alzheimer’s disease peptide β-amyloid−induced bradykinin release in human plasma. Proceedings of the National Academy of Sciences of the United States of America, 116(46): 22921–22923.
Dai W, Zhang H, Lund H, et al. 2023. Intracellular tPA–PAI-1 interaction determines VLDL assembly in hepatocytes. Science, 381(6661): eadh5207.
Fang MQ, Cha JH, Wang HC, et al. 2023a. An undefined cystatin CsCPI1 from tea plant Camellia sinensis harbors antithrombotic activity. Biomedicine & Pharmacotherapy, 159: 114285.
Fang MQ, Li Y, Liao ZY, et al. 2023b. Lipopolysaccharide-binding protein expression is increased by stress and inhibits monoamine synthesis to promote depressive symptoms. Immunity, 56(3): 620–634. e11.
Franke M, Bieber M, Kraft P, et al. 2021. The NLRP3 inflammasome drives inflammation in ischemia/reperfusion injury after transient middle cerebral artery occlusion in mice. Brain, Behavior, and Immunity, 92: 223–233.
Frazier AP, Mitchell DN, Given KS, et al. 2023. Chronic changes in oligodendrocyte sub-populations after middle cerebral artery occlusion in neonatal mice. Glia, 71(6): 1429–1450.
GBD 2019 Stroke Collaborators. 2021. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology, 20(10): 795–820.
Girolami A, Candeo N, De Marinis GB, et al. 2011. Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation. Journal of Thrombosis and Thrombolysis, 31(1): 57–63.
Gao C, Xu Y, Liang Z, et al. 2021. A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke. Acta Pharmaceutica Sinica B, 11(7): 1867–1884.
Göb E, Reymann S, Langhauser F, et al. 2015. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Annals of Neurology, 77(5): 784–803.
Göbel K, Asaridou CM, Merker M, et al. 2019. Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release. Proceedings of the National Academy of Sciences of the United States of America, 116(1): 271–276.
Hare DL, Toukhsati SR, Johansson P, et al. 2014. Depression and cardiovascular disease: a clinical review. European Heart Journal, 35(21): 1365–1372.
Holland JM. 1976. Serotonin deficiency and prolonged bleeding in beige mice. Experimental Biology and Medicine, 151(1): 32–39.
Ivanov I, Verhamme IM, Sun MF, et al. 2020. Protease activity in single-chain prekallikrein. Blood, 135(8): 558–567.
Kale SS, Villequey C, Kong XD, et al. 2018. Cyclization of peptides with two chemical bridges affords large scaffold diversities. Nature Chemistry, 10(7): 715–723.
Kearney KJ, Butler J, Posada OM, et al. 2021. Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI. Proceedings of the National Academy of Sciences of the United States of America, 118(3): e2014810118.
Kenne E, Renné T. 2014. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discovery Today, 19(9): 1459–1464.
Kim JS. 2019. tPA Helpers in the treatment of acute ischemic stroke: are they ready for clinical use?. Journal of Stroke, 21(2): 160–174.
Kleinschnitz C, Stoll G, Bendszus M, et al. 2006. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. The Journal of Experimental Medicine, 203(3): 513–518.
Lee JK, Park MS, Kim YS, et al. 2007. Photochemically induced cerebral ischemia in a mouse model. Surgical Neurology, 67(6): 620–625.
Labat-gest V, Tomasi S. 2013. Photothrombotic ischemia: a minimally invasive and reproducible photochemical cortical lesion model for mouse stroke studies. Journal of Visualized Experiments: JoVE, 76: 50370.
Li KQ, Liu GJ, Liu XY, et al. 2023a. EPAS1 prevents telomeric damage-induced senescence by enhancing transcription of TRF1, TRF2, and RAD50. Zoological Research, 44(3): 636–649.
Li XJ, Qiao CC, Chen BJ, et al. 2022. Fuel source shift or cost reduction: Context-dependent adaptation strategies in closely related Neodon fuscus and Lasiopodomys brandtii against hypoxia. Zoological Research, 43(4): 497–513.
Li YL, Jin T, Liu NX, et al. 2023b. A short peptide exerts neuroprotective effects on cerebral ischemia–reperfusion injury by reducing inflammation via the miR-6328/IKKβ/NF-κB axis. Journal of Neuroinflammation, 20(1): 53.
Long AT, Kenne E, Jung R, et al. 2016. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. Journal of Thrombosis and Haemostasis, 14(3): 427–437.
Luo J, Liang S, Jin F. 2021. Gut microbiota in antiviral strategy from bats to humans: a missing link in COVID-19. Science China Life Sciences, 64(6): 942–956.
Maetzel A, Smith MD, Duckworth EJ, et al. 2022. KVD900, an oral on-demand treatment for hereditary angioedema: phase 1 study results. Journal of Allergy and Clinical Immunology, 149(6): 2034–2042.
Nitzsche A, Poittevin M, Benarab A, et al. 2021. Endothelial S1P
Renné T. 2015. The vascular side of plasma kallikrein. Blood, 125(4): 589–590.
Renné T, Pozgajová M, GrüNer S, et al. 2005. Defective thrombus formation in mice lacking coagulation factor XII. The Journal of Experimental Medicine, 202(2): 271–281.
Revenko AS, Gao DC, Crosby JR, et al. 2011. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood, 118(19): 5302–5311.
Sala-Cunill A, Björkqvist J, Senter R, et al. 2015. Plasma contact system activation drives anaphylaxis in severe mast cell–mediated allergic reactions. Journal of Allergy and Clinical Immunology, 135(4): 1031–1043. e6.
Schumann RR, Kirschning CJ, Unbehaun A, et al. 1996. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT-3 and other cytokine-inducible nuclear proteins. Molecular and Cellular Biology, 16(7): 3490–3503.
Sheffer AL, Campion M, Levy RJ, et al. 2011. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. Journal of Allergy and Clinical Immunology, 128(1): 153–159. e4.
Shuaib A, Butcher K, Mohammad AA, et al. 2011. Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. The Lancet Neurology, 10(10): 909–921.
Simão F, Ustunkaya T, Clermont AC, et al. 2017. Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke. Blood, 129(16): 2280–2290.
Tang XP, Fang MQ, Cheng RM, et al. 2020. Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability. Circulation Research, 127(5): 651–663.
Ulanovsky N, Moss CF. 2007. Hippocampal cellular and network activity in freely moving echolocating bats. Nature Neuroscience, 10(2): 224–233.
Verstraete M, Lijnen HR. 1994. Novel thrombolytic agents. Cardiovascular Drugs and Therapy, 8(6): 801–811.
Wei XH, Zhang BP, Wei FY, et al. 2022. Gegen Qinlian pills alleviate carrageenan-induced thrombosis in mice model by regulating the HMGB1/NF-κB/NLRP3 signaling. Phytomedicine, 100: 154083.
Wilbs J, Kong XD, Middendorp SJ, et al. 2020. Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs. Nature Communications, 11(1): 3890.
Yan CC, Zhang XS, Zhou L, et al. 2020. Effects of aging on gene expression in blood of captive Tibetan macaques (Macaca thibetana) and comparisons with expression in humans. Zoological Research, 41(5): 557–563.
Yan HF, Tuo QZ, Yin QZ, et al. 2020. The pathological role of ferroptosis in ischemia/reperfusion-related injury. Zoological Research, 41(3): 220–230.
Yin SG, Pang AL, Liu CX, et al. 2022. Peptide OM-LV20 protects astrocytes against oxidative stress via the ‘PAC1R/JNK/TPH1’ axis. Journal of Biological Chemistry, 298(10): 102429.
Zamolodchikov D, Chen ZL, Conti BA, et al. 2015. Activation of the factor XII-driven contact system in Alzheimer’s disease patient and mouse model plasma. Proceedings of the National Academy of Sciences of the United States of America, 112(13): 4068–4073.
Zamolodchikov D, Renné T, Strickland S. 2016. The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII. Journal of Thrombosis and Haemostasis, 14(5): 995–1007.
Zhang P, Chen JS, Li QY, et al. 2021. Neuroprotectants attenuate hypobaric hypoxia-induced brain injuries in cynomolgus monkeys. Zoological Research, 41(1): 3–19.
Zhang ZY, Shen CB, Fang MQ, et al. 2022. Novel contact–kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke. Cellular and Molecular Life Sciences, 79(5): 240.
Zheng HY, Song TZ, Zheng YT. 2024. Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models. Zoological Research, 45(4): 747–766.
Zuraw B, Yasothan U, Kirkpatrick P. 2010. Ecallantide. Nature Reviews Drug Discovery, 9(3): 189–190.